05:59 AM EST, 12/24/2024 (MT Newswires) -- AstraZeneca ( AZN ) and Daiichi Sankyo said Tuesday they have voluntarily withdrawn their marketing authorization application in the European Union for datopotamab deruxtecan, which was intended to treat advanced or metastatic non-squamous non-small cell lung cancer.

The companies said the decision follows feedback from the European Medicines Agency's Committee for Medicinal Products for Human Use.

The companies said they remain committed to bringing the drug to lung cancer patients in the EU and will continue their clinical development program, which includes seven pivotal trials in various lung cancer settings.